Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a french cohort

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 188-194

  Guglielmetti, Lorenzo ^a,b   Le Dû, Damien ^c,d   Jachym, Mathilde ^c   Henry, Benoît ^e   Martin, Diane ^a,b   Caumes, Eric ^e   Veziris, Nicolas ^a,b,f   Métivier, Nathalie ^c   Robert, Jérôme ^a,b,f  

^a SORBONNE UNIVERSITÉ   (France)

^b Assistance publique Hôpitaux de Paris   (France)

^c Sanatorium Centre Hospitalier de Bligny ^*  (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

bedaquiline; extensively drug resistant tuberculosis; multidrug resistant tuberculosis; safety; TMC207

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; KANAMYCIN; LINEZOLID; LIVER ENZYME; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; STREPTOMYCIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPASSIONATE USE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FRANCE; HUMAN; LUNG CAVITY; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; SIDE EFFECT; ADOLESCENT; ADVERSE DRUG REACTION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924420073     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu786     Document Type: Article

References (38)

1. World Health Organization. WHO global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656- eng.pdf. Accessed 22 September 2014.
2. World Health Organization. WHO Global Task Force outlines measures to combat XDR-TB worldwide. Available at: http://www.who. int/mediacentre/news/notes/2006/np29/en/. Accessed 22 September 2014.
3. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-28.
4. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012; 9: e1001300.
5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156-68.
6. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
7. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacte-rial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51:4202-4.
8. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283:25273-80.
9. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180:553-7.
10. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2006; 51:1011-5.
11. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resis-tant tuberculosis have the potential to shorten treatment duration. Anti-microb Agents Chemother 2006; 50:3543-7.
12. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011; 6:e17556.
13. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-405.
14. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271-6.
15. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371:723-32.
16. US Food and Drug Administration. Anti-Infective Drugs Advisory Committee meeting briefing document. TMC207 (bedaquiline). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Commit teesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf. Accessed 22 September 2014.
17. Bernard C, Brossier F, Sougakoff W, et al. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Euro Surveill 2013; 18:pii:20555.
18. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Available at: http://www.ncbi.nlm.nih.gov/books/NBK154134/. Accessed 22 September 2014.
19. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160:587-93.
20. Uffredi ML, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J. An intervention programme for the management of multi-drug-resistant tuberculosis in France. Int J Antimicrob Agents 2007; 29:434-9.
21. Bazett HC. An analysis of time relations of the electrocardiograms. Heart 1920; 7:353-70.
22. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 2nd ed. Geneva, Switzerland: WHO, 2003.
23. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2013; 62:1-12.
24. Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57:4097-104.
25. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34:387-93.
26. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of mer-openem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2012; 41:1386-92.
27. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50:49-55.
28. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38:730-3.
29. Anderson L, Tamne S, Watson J, et al. Treatment outcome of multidrug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013; 18: pii:20601.
30. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28:980-5.
31. Balabanova Y, Radiulyte B, Davidaviciene E, et al. Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open 2011; 1:e000351.
32. Kim DH, Kim HJ, Park S-K, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:113-9.
33. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-5.
34. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
35. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with mul-tidrug-resistant pulmonary tuberculosis treated with ofloxacin/levoflox-acin-containing regimens. Chest 2000; 117:744-51.
36. Chien JY, Huang RM, Wang JY, et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2010; 14:616-21.
37. Sirinak C, Kittikraisak W, Pinjeesekikul D, et al. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health 2008; 8:245.
38. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56:3114-20.